13
Table 4. Routine Immunizations for HIV-Infected Adults
Vaccine Status Dose/Regimen Comments
Haemophilus
influenzae
type B
Consider in
selected settings
(see comments)
0.5 mL IM • Administer to asplenic
patients
Hepatitis A Recommended in
selected settings (see
comments)
1 mL IM with
revaccination
in 6-12 mo for
Havrix
®
or 6-18
mo for Vaqta
®
;
also available
in combination
with hepatitis
B vaccine
as Twinrix
®
administered as
3 or 4 doses
• HAV vaccination is
recommended for all
susceptible MSM as
well as others with
indications for HAV
vaccine (eg, injection
drug users, travelers
to countries of high
endemicity, persons with
chronic liver disease, or
who are infected with
hepatitis B and/or C)
• Vaccination can be
considered for all
nonimmune patients
Hepatitis B Recommended in
selected settings
(see comments)
1 dose of 40 µg/
mL (Recombivax
HB
®
) admin-
istered on a
3-dose schedule
or 2 doses of
20 µg/mL
(Engerix-B
®
)
administered
simultaneously
on a 4-dose
schedule at 0, 1,
2, and 6 mo
• Administer to patients
without evidence of past
or present hepatitis B
infection
• Vaccinated patients
should be tested for
HBsAb response 1-2
mo after or at the next
scheduled clinic visit
after the third dose
HPV Ideally given prior
to sexual activity;
indicated for
females age 9-26
and males age 9-26
Gardasil
®
0.5
mL IM for
3-dose series
given at 0, 2, and
6 mo
—
Influenza Inactivated
influenza vaccine
recommended;
do NOT use
live attenuated
intranasal vaccine
(FluMist
®
)
0.5 mL IM
annually
• All patients
• Especially important in
patients at high risk for
exposure to or morbidity
from influenza
Continued on next page
